Business Context and Reporting Period
Company: Innate Pharma SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First half of 2021 (January 1, 2021 to June 30, 2021)
Date of Report: September 15, 2021
This filing incorporates by reference a press release and the Half-Year Financial Report for the period ended June 30, 2021. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial data from the incorporated Half-Year Financial Report (Exhibit 99.2). Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in source text.
- Profit/Loss: Not provided in source text.
- Cash Flow: Not provided in source text.
- Margins: Not provided in source text.
- Debt and Liquidity: Not provided in source text.
Material Changes
The filing text does not provide specific financial figures or operational data to compare against the prior comparable period. Material changes cannot be summarized without the content of the incorporated exhibits.
Guidance, Outlook, and Risks
The cover page does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items are expected to be located within the incorporated press release (Exhibit 99.1) and financial report (Exhibit 99.2), which are not included in the input text.
Investor Verification Checklist
- Verify the full content of Exhibit 99.2 (H1 2021 Half-Year Financial Report) to obtain actual revenue, net income, and cash position figures.
- Review Exhibit 99.1 (Press Release) for specific updates on clinical trial progress, regulatory milestones, or partnership announcements.
- Confirm the company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are absent from the cover page.
- Check for any new risk factors or legal contingencies disclosed in the full financial report.